Valued at a market cap of $15.2 billion,  Viatris Inc. (VTRS) is a global pharmaceutical and healthcare company headquartered in Pennsylvania. It operates at scale across 120+ countries, focusing on expanding access to affordable medicines worldwide Companies worth $10 billion or more are typically classified as “large-cap stocks,” and Viatris fits the label perfectly, with its market cap exceeding this threshold, underscoring its size, influence, and dominance within the specialty & generic drug manufact ...

Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD) Accessibility StatementSkip Navigation Addresses a Significant Unmet Need in Japan as First and Only Approved Treatment Option for GAD PITTSBURGH, March 23, 2026 /PRNewswire/ -- Viatris Inc.(Nasdaq: VTRS), a global healthcare company, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Effexor® SR 37.5 mg / 75 mg capsules (venlafaxine hydrochloride), ...

As you know, Viatris Inc. ( VTRS ) has just outlined a pretty ambitious long-term strategy through to 2030. The aim is to transform its base business into a much more durable, higher-marginI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and challenges b ...

Viatris (NasdaqGS:VTRS) Update / briefing March 19, 2026 10:00 AM ET Company ParticipantsBill Szablewski - Head of Capital Markets and Investor RelationsCorinne Le Goff - Chief Commercial OfficerDoretta Mistras - CFOHemanth J. Varghese - Chief Strategy OfficerPhilippe Martin - Chief R&D OfficerScott Smith - CEOOperatorLadies and gentlemen, please welcome Head of Capital Markets, Viatris, Bill Szablewski.Bill SzablewskiGood morning, everyone, and welcome to our Viatris Investor Event. I'm Bill Szablewski, He ...

Investor Event Our Path to Sustained Revenue and Earnings Growth Through 2030 March 19, 2026 Forward Looking Statements This presentation contains "forward-looking statements". These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, statements about: 2026 financial guidance; long-term financial targets; base case long-term target CAGR of 3-4% for Total Revenues, 4-5% for Adjuste ...

Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030 Accessibility StatementSkip Navigation PITTSBURGH, March 19, 2026 /PRNewswire/ -- Viatris Inc.(Nasdaq: VTRS) will host its Investor Event today, where members of the executive leadership team will outline the Company's strategic vision, key drivers and financial framework expected to deliver sustained revenue and earnings growth through 2030. Executive Commentary "Over the past several years, we have taken decisive actions ...

Core Insights - Viatris Inc. (NASDAQ:VTRS) is identified as one of the extreme value stocks to consider for investment, with a medium price target of $16, indicating a potential upside of 12.36% from current levels [1] - The company reported Q4 fiscal 2025 revenue of $3.7 billion, reflecting a 1% year-over-year growth when excluding the impact from the Indore facility [2] - Viatris generated $14.3 billion in total revenue for the full year 2025 and returned over $1 billion to shareholders during the year [2] - Free cash flow for the year reached $2.2 billion, excluding transaction-related costs, with management expecting earnings and revenue to improve in the second half of 2026 [3] - The company anticipates generating between $450 million and $550 million in revenue from new product launches in 2026 [3] Financial Performance - Q4 fiscal 2025 revenue was $3.7 billion, with a 1% year-over-year growth when excluding specific impacts [2] - Full-year revenue for 2025 totaled $14.3 billion, with over $1 billion returned to shareholders [2] - Free cash flow for the year was $2.2 billion, excluding transaction costs [3] Future Outlook - Management expects earnings and revenue to improve in the second half of 2026, supported by upcoming product launches and seasonality [3] - Forecasts indicate around 2% growth in both adjusted EBITDA and total revenue for 2026 [3] - Anticipated revenue from new product launches in 2026 is projected to be between $450 million and $550 million [3] Geographic Presence - Viatris operates in multiple regions including Japan, Europe, Hong Kong, Africa, North America, Australia, the Middle East, New Zealand, Taiwan, Latin America, China, and the rest of Asia [4]

Viatris Inc. (NASDAQ:VTRS) is one of the 10 Best Stocks Under $20 to Buy According to Hedge Funds. On February 27, UBS raised its price target on Viatris Inc. (NASDAQ:VTRS) from $18 to $20 and maintained a Buy rating. UBS said the company achieved expected cost-saving targets and the company’s fiscal year 2026 guidance came in above analysts’ consensus expectations. UBS said that it is focused on Viatris Inc.’s (NASDAQ:VTRS) investor event scheduled for March 19. The firm believes the event could help ou ...

Core Viewpoint - Viatris has settled a lawsuit with the estate of Henrietta Lacks regarding the unauthorized use of her cells for drug research, with the case being dismissed with prejudice, meaning it cannot be refiled [1] Company Summary - Viatris, a generic drugmaker, faced allegations from Lacks' estate for misusing her cells to test its herpes drug Denavir and depression treatment Mylan-Mirtazapine [1] - The settlement details remain confidential, and Viatris did not respond to the allegations in court [1] Industry Context - The HeLa cell line, derived from Henrietta Lacks' tumor, has been pivotal in medical research, contributing to advancements in various fields including the polio vaccine and HIV treatments [1] - Lacks' family has previously settled lawsuits with other companies, including Novartis and Thermo Fisher, and continues to pursue legal action against Ultragenyx [1]

Market Overview - Pierre Ouimet, head investment strategist at UBS Canada, discussed market resilience amidst political friction between the US Supreme Court and President Donald Trump, noting that trade uncertainties remain due to the administration's push for a 10% global tariff [1][2] - Despite political pressures, Ouimet maintained a positive outlook, emphasizing strong broader economic fundamentals and expressing surprise at the lack of market reaction, particularly in the bond market [2] Investment Strategy - Ouimet's strategy includes reducing exposure to US dollar-denominated assets and repatriating capital to Canada or investing in Europe, advocating for wide diversification rather than focusing on a single trend or sector [3] - He remains selective within the tech sector but sees buoyancy in the AI theme, noting a third wave of development in AI and recent weakness in software stocks [4] Undervalued Sectors - Energy is highlighted as an attractive sector offering strong free cash flow yields despite a lack of investor interest, while the mining sector, particularly gold, is also identified as a strong investment opportunity [4] Company Highlights: Fidelity National Financial Inc. - Fidelity National Financial reported total annual revenue of $14.5 billion for 2025, a 7% increase year-over-year, with adjusted pre-tax earnings of $401 million in Q4 and an industry-leading margin of 17.5% [10] - The company achieved adjusted net earnings of $1.4 billion, or $4.97 per diluted share, despite a reported net loss of $117 million in Q4, supported by a 27% year-over-year increase in direct commercial revenue [11] - Technological integration played a key role, with 80% of residential sale transactions in 2025 conducted through its digital transaction platform, engaging 2.8 million unique users [12] Company Highlights: Viatris Inc. - Viatris reported total revenue of $14.3 billion for 2025, a 2% increase year-over-year, with an adjusted EBITDA of $4.2 billion and adjusted EPS of $2.35, supported by $2.2 billion in free cash flow [14] - The company anticipates total revenue and adjusted EBITDA growth of approximately 2% for 2026, with new product revenue expected to contribute between $450 million and $550 million [15] - A strategic review identified $650 million in gross cost savings to be realized through 2029, although the company faces headwinds such as uncertain FDA reinspection timing and anticipated gross margin declines [16]